NORTH CHICAGO, Ill.,
March 9, 2020 /PRNewswire/
-- AbbVie (NYSE:ABBV) today confirmed the company's activities
in the fight to address the COVID-19 public health crisis,
including supporting the experimental use of the HIV medicine,
Kaletra/Aluvia (lopinavir/ritonavir) to determine its efficacy in
the treatment of COVID-19.
The company is collaborating with select health authorities and
institutions globally to determine antiviral activity as well as
efficacy and safety of lopinavir/ritonavir against COVID-19.
AbbVie is supporting clinical studies and basic research with
lopinavir/ritonavir, working closely with European health
authorities and the U.S. Food and Drug Administration, Centers for
Disease Control and Prevention, National Institutes of Health and
Biomedical Advanced Research and Development Authority to
coordinate on these efforts. Along with industry partners, the
company has joined the Innovative Medicines Initiative to support
research and discovery of targeted medicines against
COVID-19.
"We are committed to helping in any way we can to address the
COVID-19 public health crisis, which is why we responded quickly to
the Chinese authorities' request for Aluvia in late January," said
Richard A. Gonzalez, chairman and
chief executive officer, AbbVie. "We are working with global health
authorities to ensure we meet the need of COVID-19 patients,
conduct the appropriate clinical trials to evaluate its efficacy
and ensure uninterrupted supply of the drug Kaletra/Aluvia for HIV
patients around the world."
No expected impact on drug supply
AbbVie has supplied
Kaletra/Aluvia as an experimental option for the treatment of
COVID-19 to multiple countries that have immediate patient needs
due to the outbreak. The company plans to continue to respond to
all appropriate requests for product while supporting all efforts
to determine the safety and efficacy of this therapy in this
patient population.
While helping respond to the COVID-19 crisis is a high priority,
the company is committed to protecting the supply of Kaletra/Aluvia
for HIV patients. AbbVie is actively assessing the increased demand
for Kaletra/Aluvia and has taken steps to increase supply for
COVID-19 patients without impacting treatment supply for HIV
patients.
AbbVie continues to closely monitor manufacturing and supply
chain resources around the world and does not anticipate any
disruption to its medicine supply as a result of COVID-19.
About AbbVie
AbbVie is a global, research and
development-based biopharmaceutical company committed to developing
innovative advanced therapies for some of the world's most complex
and critical conditions. The company's mission is to use its
expertise, dedicated people and unique approach to innovation to
markedly improve treatments across four primary therapeutic areas:
immunology, oncology, virology and neuroscience. In more than
75 countries, AbbVie employees are working every day to advance
health solutions for people around the world. For more information
about AbbVie, please visit us at www.abbvie.com.
Follow @abbvie on Twitter, Facebook, LinkedIn or
Instagram.
View original
content:http://www.prnewswire.com/news-releases/abbvie-partnering-with-global-authorities-to-determine-efficacy-of-hiv-drug-in-treating-covid-19-301019533.html
SOURCE AbbVie